Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of FOXO4-DRI and Humanin — mechanism, dosing, side effects, legal status, and pricing.
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.
FOXO4-DRI
Humanin
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
FOXO4-DRI
Humanin
COA corpus from Disclosed Labs — independently tested batches only.
FOXO4-DRI
5
COAs
99.5%
Avg purity
4
Labs
Humanin
3
COAs
99.5%
Avg purity
2
Labs
Baar et al. (Cell, 2017, PMID 28340339) identified FOXO4 as a pivot for senescent-cell viability and designed a cell-penetrating D-retro-inverso peptide that disrupts the FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells while sparing proliferating cells. In vivo, the peptide neutralized doxorubicin chemotoxicity and, in fast-aging XpdTTD/TTD and naturally aged mice, restored fur density, renal function, and fitness. This is the only primary in vivo study; evidence is preclinical only. No human clinical trials have been registered or completed. Safety in humans is unknown — as a systemic senolytic inducing apoptosis, theoretical risks include impaired wound healing, immune perturbation, and off-target effects on quiescent stem-cell populations.
Hashimoto et al. (2001) discovered humanin through functional screening for neuroprotective factors against amyloid-beta toxicity. Yen et al. characterized the S14G-Humanin analog (HNG) as 1000x more potent. Muzumdar et al. demonstrated that humanin improves insulin sensitivity and reduces visceral fat in animal models. Circulating humanin levels decline with age and correlate inversely with Alzheimer's biomarkers. Cohen et al. showed humanin's role in the GH/IGF-1 axis through IGFBP-3 interaction. No human clinical trials have been conducted — all dosing is extrapolated from preclinical data.
Key references
FOXO4-DRI (Metabolic) and Humanin (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs